Results 51 to 60 of about 2,713,900 (282)

After Heparin: Protecting Consumers From the Risks of Substandard and Counterfeit Drugs [PDF]

, 2011
Based on case studies, examines globalization and quality management trends in pharmaceutical manufacturing, barriers to Federal Drug Administration oversight, and the security of pharmaceutical distribution.

core  

Real-time assessment of critical quality attributes of a continuous granulation process [PDF]

, 2013
There exists the intention to shift pharmaceutical manufacturing of solid dosage forms from traditional batch production towards continuous production. The currently applied conventional quality control systems, based on sampling and time-consuming off ...
Córdoba Díaz, Damián, De Beer, Thomas, Fonteyne, Margot, Gildemyn, Delphine, Remon, Jean Paul, Vercruysse, Jurgen, Vervaet, Chris   +6 more
core   +1 more source

An isoform of 14‐3‐3 protein regulates transbilayer lipid movement at the plasma membrane

FEBS Letters, EarlyView.
Loss of 14‐3‐3ζ in CHO cells confers resistance to exogenous phosphatidylserine (PS) and impairs endocytosis‐independent inward flip‐flop of fluorescent PS at the plasma membrane. RNAi‐mediated knockdown reproduces this defect, while no additive effect is seen in ATP11C‐deficient cells.
Akiko Yamaji‐Hasegawa, Akira Hattori, Masafumi Tsujimoto, Toshihide Kobayashi   +3 more
wiley   +1 more source

Youth involvement in local pharmaceutical manufacturing in sub-Saharan Africa: barriers, recommendations, and public health implications

INNOVATIONS in Pharmacy
Background: In 2021, Africa imported 99% of its vaccines and 70% of its pharmaceuticals. As such, there has been a growing concern about and acknowledgement of the need for Africa to produce its own medicines. There are, however, only 375 pharmaceutical
Oluwaseyi Egbewande, Oladotun Okediji, Yusuf Babatunde   +2 more
doaj   +1 more source

A Perspective on the Role of Digitalization Enablers in Sustainable Pharmaceutical Manufacturing

Chemical Engineering Transactions, 2023
Due to the steady rise in the implementation of Industry 4.0 concepts in chemical and (bio)pharmaceutical industries, an essential aspect of transitioning pharmaceutical production towards Sustainable Pharmaceutical Manufacturing (SPM) is the utilization
Fatima Imran, Ruediger Lueck, Christian Jordan, Christof Herwig, Michael Harasek   +4 more
doaj   +1 more source

Continuous Crystallization Processes in Pharmaceutical Manufacturing: A Review

Organic Process Research & Development, 2020
This scientific paper presents an overview of continuous solution crystallization in the pharmaceutical industry.
J. Orehek, D. Teslič, B. Likozar
semanticscholar   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Work Organisation and Innovation - Case Study: Abbott, Ireland [PDF]

, 2013
[Excerpt] Abbott is a global, broad-based healthcare company dedicated to discovering new medicines, new technologies and new ways to manage health. Their products span the continuum of care, from nutritional products and laboratory diagnostics through ...
Ortigão, Manuel
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source